Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 5/2013

01-05-2013 | Educational Series - Blue Series

Polymorphisms in HIF-1alpha affect presence of lymph node metastasis and can influence tumor size in squamous-cell carcinoma of the glottic larynx

Authors: F. Mera-Menéndez, A. Hinojar-Gutiérrez, M. Guijarro Rojas, J. García de Gregorio, E. Mera-Menéndez, J. J. Sánchez, M. Quintanilla, L. Cerezo, C. Gamallo

Published in: Clinical and Translational Oncology | Issue 5/2013

Login to get access

Abstract

Background

HIF-1alpha plays a key role in the development and progression of cancer. Its polymorphic variants C1772T and G1790A have been associated with greater susceptibility to cancer and increased tumor progression.

Methods

We determined the distribution of these polymorphisms among 121 patients with glottic cancer and 154 healthy volunteers by PCR–RFLP. We also analyzed the relationship between the presence of these polymorphisms and various clinicopathologic variables.

Results

Advanced tumors (T3–T4) were associated with the TT variant (p = 0.036), which was present in 75 % of T4 tumors (p = 0.008).
Among patients with nodal metastasis (N+), 41.7 and 22 % were carrying the TT and GA variants, respectively, compared with 9.4 and 2 % of the patients with no metastasis (N0), (p = 0.006 and p = 0.032).

Conclusions

The presence of the TT and GA variants were associated with lymph node metastasis, while the presence of the TT variant can be associated with larger tumor size.
Appendix
Available only for authorised users
Literature
1.
Parkin DM, Whelan SL, Ferlay J, Storm H (2005) Cancer incidence in five continents: vol. I, to VIII. IARC Cancer Base, No 7, Lyon
2.
Almadori G, Bussu F, Cadoni G, Galli J, Paludetti G, Maurizi M (2005) Molecular markers in laryngeal squamous cell carcinoma: towards an integrated clinicobiological approach. Eur J Cancer 41:683–693PubMedCrossRef
3.
Bartsch H, Dally H, Popanda O, Risch A, Schmezer P (2007) Genetic risk profiles for cancer susceptibility and therapy response. Recent Results Cancer Res 174:19–36PubMedCrossRef
4.
Vaupel P, Mayer A, Höckel M (2004) Tumor hypoxia and malignant progression. Methods Enzymol 381:335–354PubMedCrossRef
5.
Acker T, Plate KH (2002) A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology. J Mol Med 80:562–575PubMedCrossRef
6.
Hirota K, Semenza G (2006) Regulation of angiogénesis by hypoxia-inducible factor I. Crit Rev Oncol Hematol 59:15–26PubMedCrossRef
7.
Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K (2003) Hypoxia-inducible factor-1 alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis 24:1779–1783PubMedCrossRef
8.
Secades P, Rodrigo J, Hermsen M, Alvarez C, Suarez C, Chiara MD (2009) Increase in gene dosage is a mechanism of HIF-1alpha constitutive expression in head and neck squamous cell carcinomas. Genes Chromosom Cancer 48:441–454PubMedCrossRef
9.
Clifford SC, Astuti D, Hooper L, Maxwell PH, Ratcliffe PJ, Maher ER (2001) The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Oncogene 20:5067–5074PubMedCrossRef
10.
Zhao T, Lv J, Zhao J, Nzekebaloudou M (2009) Hypoxia inducible factor-1 alpha gene polymorphisms and cancer risk: a meta-analysis. J Exp Clin Cancer Res 28:159PubMedCrossRef
11.
12.
Warren S, Gates O (1932) Multiple malignant tumors: a survey of literature and statistical study. Am J Cancer 51:1358–1414
13.
Fransén K, Fenech M, Fredrikson M, Dabrosin C, Söderkvist P (2006) Association between ulcerative growth and hypoxia inducible factor-1 alpha polymorphisms in colorectal cancer patients. Mol Carcinog 45:833–840PubMedCrossRef
14.
15.
Weinberg W (1908) Über den Nachweis der Vererbung beim Menschen. Jahreshefle des Vereins für vaterländische Naturkunde in Württemberg 64:368–382
16.
17.
18.
Bartsch H, Hietanen E (1996) The role of individual susceptibility in cancer burden related to environmental exposure. Environ Health Perspect 104:569–577PubMed
19.
Abbasi R, Ramroth H, Becher H, Dietz A, Schmezer P, Popanda O (2009) Laryngeal cancer risk associated with smoking and alcohol consumption is modified by genetic polymorphisms in ERCC5, ERC6 and RAD23B but not polymorphisms in five other nucleotide excision repair genes. Int J Cancer 125:1431–1439PubMedCrossRef
20.
Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH (1994) Systematic population based assessment of cancer risk in first-degree relative of cancer probands. J Natl Cancer Inst 86:1600–1608PubMedCrossRef
21.
Foulkes WD, Brunet JS, Sieh W, Black MJ, Shenouda G, Narod SA (1996) Familial risks of squamous cell carcinoma of the head and neck: retrospective case-control study. BMJ 313:716–721PubMedCrossRef
22.
Cui Y, Morgenstern H, Greenland S et al (2006) Polymorphism of xeroderma pigmentosum group G and the risk of lung cancer and squamous cell carcinoma of the oropharynx, larynx and esophagus. Int J Cancer 118:714–720PubMedCrossRef
23.
Sturgis EM, Wei Q (2002) Genetic susceptibility-molecular epidemiology of head and neck cancer. Curr Opin Oncol 14:310–317PubMedCrossRef
24.
Katsuta M, Miyashita M, Makino H et al (2005) Correlation of hypoxia inducible factor-1alpha with lymphatic metastasis via vascular endothelial growth factor-C in human esophageal cancer. Exp Mol Pathol 78:123–130PubMedCrossRef
25.
Batmunkh E, Shimada M, Morine Y et al (2010) Expression of hypoxia inducible factor -1 alpha (HIF-1alpha) in patients with gallbladder carcinoma. Int J Clin Oncol 15:59–64PubMedCrossRef
26.
Aebersold DM, Burri P, Beer KT et al (2001) Expression of hypoxia inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 61:2911–2916PubMed
27.
Lin PY, Yu CH, Wang JT, Chiang CP et al (2008) Expression of hypoxia-inducible factor-1 alpha is significantly associated with the progression and prognosis of oral squamous cell carcinoma in Taiwan. J Oral Pathol Med 37:18–25PubMedCrossRef
28.
Muñoz-Guerra MF, Fernández-Contreras ME, Moreno AL, Martín ID, Herráez B, Gamallo C (2009) Polymorphisms in the hypoxia inducible factor 1-alpha and the impact on the prognosis of early stages of oral cancer. Ann Surg Oncol 16:2351–2358PubMedCrossRef
29.
Chen MK, Chiou H, Su SC et al (2009) The association between hypoxia inducible factor-1alpha gene polymorphisms and increased susceptibility to oral cancer. Oral Oncol 45:222–226CrossRef
Metadata
Title
Polymorphisms in HIF-1alpha affect presence of lymph node metastasis and can influence tumor size in squamous-cell carcinoma of the glottic larynx
Authors
F. Mera-Menéndez
A. Hinojar-Gutiérrez
M. Guijarro Rojas
J. García de Gregorio
E. Mera-Menéndez
J. J. Sánchez
M. Quintanilla
L. Cerezo
C. Gamallo
Publication date
01-05-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 5/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0930-z

Other articles of this Issue 5/2013

Clinical and Translational Oncology 5/2013 Go to the issue

Research Article

Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib

Research Article

Dose–volume histogram parameters for predicting radiation pneumonitis using receiver operating characteristic curve

Research Article

Clinical report on transarterial neoadjuvant chemotherapy of malignant fibrous histiocytoma in soft tissue

Educational Series – Blue Series

MicroRNAs and drug resistance of breast cancer: basic evidence and clinical applications

Educational Series – Red Series

An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents

Brief Research Article

Cone-beam computed tomography dose monitoring during intensity-modulated radiotherapy in head and neck cancer: parotid glands
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits